Recombinant human leukemia inhibitory factor does not enhance in vitro human blastocyst formation

Fertil Steril. 1995 Nov;64(5):999-1002.

Abstract

Objective: To assess the effect of human recombinant leukemia inhibitory factor in different doses on human blastocyst formation.

Setting: A university-based tertiary referral center (The Toronto Hospital).

Interventions: Nontransferable human embryos (n = 473) at the two- to six-cell stage were obtained from patients undergoing IVF and were split randomly into five groups. Embryos in group A (n = 164) were cultured as the control group in Ham's F-10 (GIBCO-BRL, Grand Island, NY) + 10% human sera. Embryos in groups B, C, D, and E (n = 54, 78, 87, and 80, respectively) were cultured in the same medium supplemented with human recombinant leukemia inhibitory factor in four different concentrations (5, 7.5, 10, and 20 ng/mL, respectively). Morphological assessment of embryo development was recorded daily.

Main outcome measure: Human blastocyst formation.

Results: No significant difference was detected in the rate of blastocyst formation of embryos in the study groups when compared with embryos in group A.

Conclusions: This study shows that 5 to 20 ng/mL of recombinant leukemia inhibitory factor in standard medium does not enhance in vitro human blastocyst formation. It is possible that recombinant leukemia inhibitory factor may play a role at later stages of human embryogenesis and during implantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blastocyst / drug effects*
  • Blastocyst / physiology
  • Dose-Response Relationship, Drug
  • Embryonic and Fetal Development / drug effects
  • Embryonic and Fetal Development / physiology
  • Female
  • Fertilization in Vitro
  • Growth Inhibitors / pharmacology*
  • Humans
  • Interleukin-6*
  • Leukemia Inhibitory Factor
  • Lymphokines / pharmacology*
  • Recombinant Proteins / pharmacology

Substances

  • Growth Inhibitors
  • Interleukin-6
  • LIF protein, human
  • Leukemia Inhibitory Factor
  • Lymphokines
  • Recombinant Proteins